Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children
Updated: November 19, 2026
- Pediatric heart failure (HF) arises from structural or functional cardiac disorders that impair ventricular filling and/or ejection. It is a complex condition with heterogeneous presentations driven by diverse etiologies and is associated with substantial morbidity, mortality, and health care burden.
- Guideline-directed medical therapy (GDMT), including angiotensin receptor–neprilysin inhibitors (ARNIs), sodium–glucose cotransporter 2 inhibitors (SGLT2i), and intravenous iron, remain under-investigated in children and are inconsistently prescribed, often requiring clinicians to extrapolate from adult data or practice without formal guidance.
- This science advisory details results from a survey of pediatric HF clinicians in the United States and Canada, focusing on prescribing practices, side effects, dosing experience, and clinician perspectives on the use of ARNIs, SGLT2i, and iron replacement therapy in children.